Litcius/Paper detail

Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications

Byoung Chul Cho, Allison K. Simi, Joshua K. Sabari, Smruthi Vijayaraghavan, Sheri L. Moores, Alexander I. Spira

2022Clinical Lung Cancer133 citationsDOIOpen Access PDF

Topics & Concepts

Epidermal growth factor receptorMedicineCancer researchMesenchymal stem cellLung cancerTargeted therapyGrowth factor receptorAntibodyIn vivoMonoclonal antibodyImmune systemReceptorCancerImmunologyOncologyInternal medicineBiologyPathologyBiotechnologyLung Cancer Treatments and MutationsLung Cancer Research StudiesCancer therapeutics and mechanisms
Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications | Litcius